Immunotherapy of AML

Gheath Alatrash; Jeffrey J. Molldrem

doi:10.1007/978-0-387-69259-3_14

Immunotherapy of AML

Gheath Alatrash, Jeffrey J. Molldrem

Stem Cell Transplantation

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Scopus citations

Abstract

The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6]. In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches.

Original language	English (US)
Title of host publication	Acute Myelogenous Leukemia
Subtitle of host publication	Genetics, Biology and Therapy
Editors	Lalitha Nagarajan
Pages	237-255
Number of pages	19
DOIs	https://doi.org/10.1007/978-0-387-69259-3_14
State	Published - 2010

Publication series

Name	Cancer Treatment and Research
Volume	145
ISSN (Print)	0927-3042

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/978-0-387-69259-3_14

Cite this

@inbook{70f28536e97b4bc6a75eb15f1e1510bf,

title = "Immunotherapy of AML",

abstract = "The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6]. In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches.",

author = "Gheath Alatrash and Molldrem, {Jeffrey J.}",

year = "2010",

doi = "10.1007/978-0-387-69259-3_14",

language = "English (US)",

isbn = "9780387692579",

series = "Cancer Treatment and Research",

pages = "237--255",

editor = "Lalitha Nagarajan",

booktitle = "Acute Myelogenous Leukemia",

}

TY - CHAP

T1 - Immunotherapy of AML

AU - Alatrash, Gheath

AU - Molldrem, Jeffrey J.

PY - 2010

Y1 - 2010

N2 - The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6]. In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches.

AB - The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6]. In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches.

UR - http://www.scopus.com/inward/record.url?scp=77956152185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956152185&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-69259-3_14

DO - 10.1007/978-0-387-69259-3_14

M3 - Chapter

C2 - 20306255

AN - SCOPUS:77956152185

SN - 9780387692579

T3 - Cancer Treatment and Research

SP - 237

EP - 255

BT - Acute Myelogenous Leukemia

A2 - Nagarajan, Lalitha

ER -

Immunotherapy of AML

Abstract

Publication series

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this